Literature DB >> 20930048

Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism.

Jiansheng Huang1, Imene Tabbi-Anneni, Viswanath Gunda, Li Wang.   

Abstract

Nuclear factor erythroid-2 related factor 2 (Nrf2) plays a pivotal role in cytoprotection against both endogenous and exogenous stresses. Here, we establish a novel molecular link between Nrf2, nuclear receptor small heterodimer partner (SHP; NROB2), lipogenic genes, and hepatic lipid homeostasis. Deletion of Nrf2 (Nrf2⁻(/)⁻) in mice resulted in a reduced liver weight, a decrease in fatty acid content of hepatic triacylglycerol, as well as concomitant increases in the levels of serum VLDL-triglyceride (TG), HDL cholesterol, and ketone bodies at 6 mo of age. Liver weight and hepatic TG content were consistently lower in Nrf2⁻(/)⁻ mice upon a high-fat challenge. This phenotype was accompanied by downregulation of genes in lipid synthesis and uptake and upregulation of genes in lipid oxidation in older Nrf2⁻(/)⁻ mice. Interestingly, SHP expression was induced with age in Nrf2(+/+) mice but decreased by Nrf2 deficiency. Forced expression and activation of Nrf2 by Nrf2 activators consistently induced SHP expression, and Nrf2 was identified as a novel activator of the SHP gene transcription. We also identified PPAR-γ, Fas, Scd1, and Srebp-1 as direct targets of Nrf2 activation. These findings provide evidence for a role of Nrf2 in the modulation of hepatic lipid homeostasis through transcriptional activation of SHP and lipogenic gene expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930048      PMCID: PMC3006243          DOI: 10.1152/ajpgi.00322.2010

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  44 in total

Review 1.  Chemoprotection against cancer by induction of phase 2 enzymes.

Authors:  P Talalay
Journal:  Biofactors       Date:  2000       Impact factor: 6.113

2.  Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene.

Authors:  R Venugopal; A K Jaiswal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates.

Authors:  B Staels; A van Tol; G Skretting; J Auwerx
Journal:  J Lipid Res       Date:  1992-05       Impact factor: 5.922

4.  NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development.

Authors:  K Chan; R Lu; J C Chang; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

5.  Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism.

Authors:  Ke Ma; Mehmet Cilingiroglu; James D Otvos; Christie M Ballantyne; Ali J Marian; Lawrence Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

6.  Resistance of SHP-null mice to bile acid-induced liver damage.

Authors:  Li Wang; Yunqing Han; Chang-Soo Kim; Yoon-Kwang Lee; David D Moore
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

7.  Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain.

Authors:  K Itoh; N Wakabayashi; Y Katoh; T Ishii; K Igarashi; J D Engel; M Yamamoto
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

8.  Transcriptional co-activator activity of SYT is negatively regulated by BRM and Brg1.

Authors:  Michiko Ishida; Shinya Tanaka; Misao Ohki; Tsutomu Ohta
Journal:  Genes Cells       Date:  2004-05       Impact factor: 1.891

9.  Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2).

Authors:  Ken Itoh; Mie Mochizuki; Yukio Ishii; Tetsuro Ishii; Takahiro Shibata; Yoshiyuki Kawamoto; Vincent Kelly; Kiyohisa Sekizawa; Koji Uchida; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver.

Authors:  Paolo Parini; Matthew Davis; Aaron T Lada; Sandra K Erickson; Teresa L Wright; Ulf Gustafsson; Staffan Sahlin; Curt Einarsson; Mats Eriksson; Bo Angelin; Hiroshi Tomoda; Satoshi Omura; Mark C Willingham; Lawrence L Rudel
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

View more
  77 in total

1.  Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1).

Authors:  Beatriz Aranda-Orgillés; Désirée Rutschow; Raphael Zeller; Antonios I Karagiannidis; Andrea Köhler; Changwei Chen; Timothy Wilson; Sven Krause; Stefan Roepcke; David Lilley; Rainer Schneider; Susann Schweiger
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.

Authors:  Jiansheng Huang; Yuzhi Jia; Tao Fu; Navin Viswakarma; Liang Bai; M Sambasiva Rao; Yijun Zhu; Jayme Borensztajn; Janardan K Reddy
Journal:  FASEB J       Date:  2011-10-18       Impact factor: 5.191

3.  Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice.

Authors:  Zhigang Wang; Xiaobing Dou; Songtao Li; Ximei Zhang; Xinguo Sun; Zhanxiang Zhou; Zhenyuan Song
Journal:  Hepatology       Date:  2014-02-25       Impact factor: 17.425

4.  Multiple roles of Nrf2-Keap1 signaling: regulation of development and xenobiotic response using distinct mechanisms.

Authors:  Huai Deng
Journal:  Fly (Austin)       Date:  2013-11-01       Impact factor: 2.160

5.  Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Authors:  Daniel M Rotroff; Sonja S Pijut; Skylar W Marvel; John R Jack; Tammy M Havener; Aurora Pujol; Agatha Schluter; Gregory A Graf; Henry N Ginsberg; Hetal S Shah; He Gao; Mario-Luca Morieri; Alessandro Doria; Josyf C Mychaleckyi; Howard L McLeod; John B Buse; Michael J Wagner; Alison A Motsinger-Reif
Journal:  Clin Pharmacol Ther       Date:  2017-11-03       Impact factor: 6.875

6.  Regulation of position effect variegation at pericentric heterochromatin by Drosophila Keap1-Nrf2 xenobiotic response factors.

Authors:  Jennifer Carlson; Thane Swisse; Charles Smith; Huai Deng
Journal:  Genesis       Date:  2019-03-19       Impact factor: 2.487

7.  Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.

Authors:  Robin H Isaacson; Juliane I Beier; Nicholas Kh Khoo; Bruce A Freeman; Zachary Freyberg; Gavin E Arteel
Journal:  J Nutr Biochem       Date:  2020-04-08       Impact factor: 6.048

8.  Nrf2 participates in regulating maternal hepatic adaptations to pregnancy.

Authors:  Yuhong Zou; Min Hu; Qi Bao; Jefferson Y Chan; Guoli Dai
Journal:  J Cell Sci       Date:  2013-02-15       Impact factor: 5.285

9.  Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor γ Essential for Resistance to Crescentic GN.

Authors:  Carole Henique; Guillaume Bollee; Olivia Lenoir; Neeraj Dhaun; Marine Camus; Anna Chipont; Kathleen Flosseau; Chantal Mandet; Masayuki Yamamoto; Alexandre Karras; Eric Thervet; Patrick Bruneval; Dominique Nochy; Laurent Mesnard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

10.  Comparison of Hepatic NRF2 and Aryl Hydrocarbon Receptor Binding in 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Treated Mice Demonstrates NRF2-Independent PKM2 Induction.

Authors:  Rance Nault; Claire M Doskey; Kelly A Fader; Cheryl E Rockwell; Tim Zacharewski
Journal:  Mol Pharmacol       Date:  2018-05-11       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.